BACKGROUND: HIV prevalence is low in the Middle East and North Africa (MENA) region, though the risk or potential for further spread in the future is not well understood. Behavioral surveys are limited in this region and when available have serious limitations in assessing the risk of HIV acquisition. We demonstrate the potential use of herpes simplex virus-2 (HSV-2) seroprevalence as a marker for HIV risk within MENA. METHODS: We designed a mathematical model to assess whether HSV-2 prevalence can be predictive of future HIV spread. We also conducted a systematic literature review of HSV-2 seroprevalence studies within MENA. RESULTS: We found that HSV-2 prevalence data are rather limited in this region. Prevalence is typically low among the general population but high in established core groups prone to sexually transmitted infections such as men who have sex with men and female sex workers. Our model predicts that if HSV-2 prevalence is low and stable, then the risk of future HIV epidemics is low. However, expanding or high HSV-2 prevalence (greater than about 20%), implies a risk for a considerable HIV epidemic. Based on available HSV-2 prevalence data, it is not likely that the general population in MENA is experiencing or will experience such a considerable HIV epidemic. Nevertheless, the risk for concentrated HIV epidemics among several high-risk core groups is present. CONCLUSIONS: HSV-2 prevalence surveys provide a useful mechanism for identifying and corroborating populations at risk for HIV within MENA. HSV-2 serology offers an effective tool for probing hidden sexual risk behaviors in a region where quality behavioral data are limited.
BACKGROUND: HIV prevalence is low in the Middle East and North Africa (MENA) region, though the risk or potential for further spread in the future is not well understood. Behavioral surveys are limited in this region and when available have serious limitations in assessing the risk of HIV acquisition. We demonstrate the potential use of herpes simplex virus-2 (HSV-2) seroprevalence as a marker for HIV risk within MENA. METHODS: We designed a mathematical model to assess whether HSV-2 prevalence can be predictive of future HIV spread. We also conducted a systematic literature review of HSV-2 seroprevalence studies within MENA. RESULTS: We found that HSV-2 prevalence data are rather limited in this region. Prevalence is typically low among the general population but high in established core groups prone to sexually transmitted infections such as men who have sex with men and female sex workers. Our model predicts that if HSV-2 prevalence is low and stable, then the risk of future HIV epidemics is low. However, expanding or high HSV-2 prevalence (greater than about 20%), implies a risk for a considerable HIV epidemic. Based on available HSV-2 prevalence data, it is not likely that the general population in MENA is experiencing or will experience such a considerable HIV epidemic. Nevertheless, the risk for concentrated HIV epidemics among several high-risk core groups is present. CONCLUSIONS:HSV-2 prevalence surveys provide a useful mechanism for identifying and corroborating populations at risk for HIV within MENA. HSV-2 serology offers an effective tool for probing hidden sexual risk behaviors in a region where quality behavioral data are limited.
Authors: M J van de Laar; F Termorshuizen; M J Slomka; G J van Doornum; J M Ossewaarde; D W Brown; R A Coutinho; J A van den Hoek Journal: Int J Epidemiol Date: 1998-02 Impact factor: 7.196
Authors: Fujie Xu; Maya R Sternberg; Benny J Kottiri; Geraldine M McQuillan; Francis K Lee; Andre J Nahmias; Stuart M Berman; Lauri E Markowitz Journal: JAMA Date: 2006-08-23 Impact factor: 56.272
Authors: Jairam R Lingappa; Jared M Baeten; Anna Wald; James P Hughes; Katherine K Thomas; Andrew Mujugira; Nelly Mugo; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; James Kiarie; Carey Farquhar; Grace John Stewart; Joseph Makhema; Myron Essex; Edwin Were; Kenneth H Fife; Guy de Bruyn; Glenda E Gray; James A McIntyre; Rachel Manongi; Saidi Kapiga; David Coetzee; Susan Allen; Mubiana Inambao; Kayitesi Kayitenkore; Etienne Karita; William Kanweka; Sinead Delany; Helen Rees; Bellington Vwalika; Amalia S Magaret; Richard S Wang; Lara Kidoguchi; Linda Barnes; Renee Ridzon; Lawrence Corey; Connie Celum Journal: Lancet Date: 2010-02-12 Impact factor: 79.321
Authors: L Platt; P Vickerman; M Collumbien; S Hasan; N Lalji; S Mayhew; R Muzaffar; A Andreasen; S Hawkes Journal: Sex Transm Infect Date: 2009-04 Impact factor: 3.519
Authors: S Hawkes; M Collumbien; L Platt; N Lalji; N Rizvi; A Andreasen; J Chow; R Muzaffar; H ur-Rehman; N Siddiqui; S Hasan; A Bokhari Journal: Sex Transm Infect Date: 2009-04 Impact factor: 3.519
Authors: Marcia M Hobbs; Sophie W Mwanyumba; Winnie K Luseno; Shane Hartman; Carolyn T Halpern; Denise D Hallfors; Hyunsan Cho Journal: Sex Transm Dis Date: 2017-02 Impact factor: 2.830
Authors: Narat Punyacharoensin; William John Edmunds; Daniela De Angelis; Richard Guy White Journal: Eur J Epidemiol Date: 2011-09-20 Impact factor: 8.082
Authors: S Asgari; L Chamani-Tabriz; S Asadi; F Fatemi; H Zeraati; M M Akhondi; A Shahnazi Journal: Iran Red Crescent Med J Date: 2011-11-01 Impact factor: 0.611
Authors: Wim Delva; David P Wilson; Laith Abu-Raddad; Marelize Gorgens; David Wilson; Timothy B Hallett; Alex Welte Journal: PLoS Med Date: 2012-07-10 Impact factor: 11.069
Authors: Molly R Petersen; Eshan U Patel; M Kate Grabowski; Charlotte A Gaydos; Thomas C Quinn; Aaron A R Tobian Journal: Clin Infect Dis Date: 2021-08-02 Impact factor: 9.079